• Title of article

    Mutual enhancement between heparanase and vascular endothelial growth factor: A novel mechanism for melanoma progression

  • Author/Authors

    Luan، نويسنده , , Qi and Sun، نويسنده , , Jing and Li، نويسنده , , Chunying and Zhang، نويسنده , , Guoyou and Lv، نويسنده , , Yajie and Wang، نويسنده , , Gang and Li، نويسنده , , Chengxin and Ma، نويسنده , , Cuiling and Gao، نويسنده , , Tianwen، نويسنده ,

  • Issue Information
    روزنامه با شماره پیاپی سال 2011
  • Pages
    12
  • From page
    100
  • To page
    111
  • Abstract
    Heparanase is closely related to growth factors in the role of promoting tumor progression. Among them, vascular endothelial growth factor (VEGF) is necessary for tumor vascularity and metastasis. Release of VEGF by heparanase can initiate relative signaling pathways, resulting in an up-regulation of transcriptional factors related with heparanase. Therefore, VEGF likely has a potential function as a regulator of heparanase expression in melanoma. We hypothesized that a novel mechanism exists where heparanase and VEGF are mutually enhanced in melanoma. Our study was conducted to validate the hypothetical mutual enhancement and elucidate its effect on melanoma progression. We found that the addition of exogenous VEGF and its cDNA transfection induce heparanase over-expression by means of western-blot and real-time RT-PCR, while anti-VEGF siRNA reduces heparanase expression in A2058 and WM793 melanoma cell lines. Likewise, VEGF expression is also regulated by heparanase in these two cell lines. Additionally, the cells with mutual enhancement phenotypes exhibit higher proliferation and transmigration capacity. PD98059, a specific inhibitor of the MEK/ERK signaling pathway, is involved in this mutual enhancement. These data are the first to show that heparanase and VEGF have a mutual enhancement in melanoma cells, which may be a novel mechanism for promoting melanoma progression.
  • Keywords
    heparanase , melanoma , Vascular endothelial growth factor (VEGF) , MEK/ERK pathway
  • Journal title
    Cancer Letters
  • Serial Year
    2011
  • Journal title
    Cancer Letters
  • Record number

    1820123